Judge Approves $69 Million ChemoCentryx Investor Settlement
A federal court settled claims that the biotech company misled investors regarding its vasculitis drug safety profile.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust that legal settlements in class-action cases prioritize the interests of investors over attorneys?
A federal judge in California has granted final approval to a $69 million settlement resolving a class-action lawsuit against ChemoCentryx. The litigation alleged the company misrepresented the safety of a drug intended to treat vasculitis.
Why it matters
The settlement concludes claims from investors who alleged that ChemoCentryx provided misleading information about their drug development. It provides compensation to those who held company stock during the period when safety concerns were at issue.
The court approved $15.2 million for attorneys' fees and $4.9 million for litigation expenses, which represents 22% of the total settlement fund. The settlement covers individuals who acquired ChemoCentryx stock between November 26, 2019, and May 6, 2021.
The players
ChemoCentryx
A biotechnology company that focuses on discovering and developing oral therapies for inflammatory and autoimmune diseases and cancer.
Jon S. Tigar
A United States District Judge serving on the United States District Court for the Northern District of California.
The details
Judge Jon S. Tigar of the US District Court for the Northern District of California signed the order finalizing the agreement. The class-action suit accused the biotech firm of overstating the safety profile of its vasculitis treatment to shareholders.
Timeline
The class action eligibility period ran from November 26, 2019, to May 6, 2021.
The judge granted final approval for the settlement on October 29, 2026.
The Tech Race
This settlement highlights the persistent legal risks inherent in the rapid development cycles of the biotech industry. Companies must balance the high-stakes pressure to bring therapies to market with rigorous disclosure standards to avoid costly litigation regarding drug safety claims.
Eligible investors who purchased stock during the specified timeframe are now positioned to receive compensation from the $69 million fund. The settlement provides a clear, court-mandated resolution to claims that previously created market uncertainty regarding the company's financial and regulatory standing.
The takeaway
This case serves as a reminder of the importance of transparency in clinical trial reporting for public biotech companies. Investors should remain cautious about potential discrepancies between internal safety data and public corporate communications.
Further reading
For more on the industry, visit the Biotech section.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Do you trust that legal settlements in class-action cases prioritize the interests of investors over attorneys?
